Loading
18F-MK-6240 radiopharmaceutical / Alzheimer Disease / 18F-Flortaucipir radiopharmaceutical · Phase 1 Trial
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 interventional study registration comparing tau PET tracers 18F-Flortaucipir and 18F-MK-6240 in Alzheimer's disease, with amyloid-β imaging as an adjunct. No results are posted in this registry record; the study is active but not recruiting, with primary outcomes measured at 2 and 5 years post-enrollment.
Phase 1, Interventional, Single Group, Open label, Diagnostic purpose. Alzheimer Disease; age from 18 Years; to 90 Years; accepts healthy volunteers. Intervention: Individuals across the aging and Alzheimer's disease (AD) s…. Compared with: Direct comparison between 18F-Flortaucipir and 18F-MK-6240 tau tracers.. n = 822. 9 sites: United States, Canada, Spain.
This is a Phase 1 interventional study registration comparing tau PET tracers 18F-Flortaucipir and 18F-MK-6240 in Alzheimer's disease, with amyloid-β imaging as an adjunct. No results are posted in this registry record; the study is active but not recruiting, with primary outcomes measured at 2 and 5 years post-enrollment.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
When results are available, this head-to-head harmonization may inform choice of tau PET tracer for clinical trials and practice, and may provide conversion parameters between tracers. Currently, no clinical recommendations can be drawn from this registry entry.
This is an active interventional Phase 1 registry record with no published results; it describes a planned head-to-head harmonization study of tau PET tracers in Alzheimer's disease.
As stated by the source record.
Quoted from the source exactly as published.
When results are available, this head-to-head harmonization may inform choice of tau PET tracer for clinical trials and practice, and may provide conversion parameters between tracers. Currently, no clinical recommendations can be drawn from this registry entry.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05361382). This is a study registration, not published results. Lead sponsor: Tharick Pascoal. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 822 participants (ACTUAL). Conditions: Alzheimer Disease. Interventions: DRUG: 18F-Flortaucipir radiopharmaceutical; DRUG: 18F-MK-6240 radiopharmaceutical; DRUG: Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol). Primary outcome measures: Cross-sectional tau PET uptake values , 2 years from enrollment; Longitudinal change in tau PET uptake values over 18 months , 5 years from enrollment. Brief summary: The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.